Survival and relapse by immune cell type
| Variable . | . | Multivariable . | ||
|---|---|---|---|---|
| Total no. of patients . | RR/HR . | 95% CI . | P . | |
| TRM at day 100 | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.66-7.77 | .20 |
| Lower (<43.8) | 31 | 2.26 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.33-6.28 | .63 |
| Lower (<34.8) | 66 | 1.44 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 1.27-14.39 | .02 |
| Lower (<8.9) | 16 | 4.27 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 1.26-14.39 | .02 |
| Lower (<1.3) | 15 | 4.26 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.60-5.06 | .31 |
| Lower (<0.4) | 56 | 1.74 | ||
| DFS at 1 y | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.83-2.66 | .18 |
| Lower (<43.8) | 31 | 1.49 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.45-1.35 | .36 |
| Lower (<34.8) | 66 | 0.77 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.77-3.22 | .21 |
| Lower (<8.9) | 16 | 1.58 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.58-2.59 | .60 |
| Lower (<1.3) | 15 | 1.22 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4 cells/μL) | 97 | 1.0 | 0.64-1.74 | .84 |
| Lower (<0.4 cells/μL) | 56 | 1.05 | ||
| OS at 1 y | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.76-2.97 | .24 |
| Lower (<43.8) | 31 | 1.51 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.55-2.06 | .84 |
| Lower (<34.8) | 66 | 1.07 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.74-3.83 | .22 |
| Lower (<8.9) | 16 | 1.68 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.80-4.31 | .15 |
| Lower (<1.3) | 15 | 1.86 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.81-2.70 | .20 |
| Lower (<0.4) | 56 | 1.48 | ||
| Relapse at 1 y | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.62-2.60 | .52 |
| Lower (<43.8) | 31 | 1.27 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.40-1.60 | .53 |
| Lower (<34.8) | 66 | 0.80 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.28-2.29 | .67 |
| Lower (<8.9) | 16 | 0.80 | ||
| CD4+ naive T cells (CD45RA+ CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.15-1.73 | .27 |
| Lower (<1.3) | 15 | 0.50 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.33-1.28 | .21 |
| Lower (<0.4) | 56 | 0.65 | ||
| Variable . | . | Multivariable . | ||
|---|---|---|---|---|
| Total no. of patients . | RR/HR . | 95% CI . | P . | |
| TRM at day 100 | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.66-7.77 | .20 |
| Lower (<43.8) | 31 | 2.26 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.33-6.28 | .63 |
| Lower (<34.8) | 66 | 1.44 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 1.27-14.39 | .02 |
| Lower (<8.9) | 16 | 4.27 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 1.26-14.39 | .02 |
| Lower (<1.3) | 15 | 4.26 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.60-5.06 | .31 |
| Lower (<0.4) | 56 | 1.74 | ||
| DFS at 1 y | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.83-2.66 | .18 |
| Lower (<43.8) | 31 | 1.49 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.45-1.35 | .36 |
| Lower (<34.8) | 66 | 0.77 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.77-3.22 | .21 |
| Lower (<8.9) | 16 | 1.58 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.58-2.59 | .60 |
| Lower (<1.3) | 15 | 1.22 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4 cells/μL) | 97 | 1.0 | 0.64-1.74 | .84 |
| Lower (<0.4 cells/μL) | 56 | 1.05 | ||
| OS at 1 y | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.76-2.97 | .24 |
| Lower (<43.8) | 31 | 1.51 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.55-2.06 | .84 |
| Lower (<34.8) | 66 | 1.07 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.74-3.83 | .22 |
| Lower (<8.9) | 16 | 1.68 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.80-4.31 | .15 |
| Lower (<1.3) | 15 | 1.86 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.81-2.70 | .20 |
| Lower (<0.4) | 56 | 1.48 | ||
| Relapse at 1 y | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.62-2.60 | .52 |
| Lower (<43.8) | 31 | 1.27 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.40-1.60 | .53 |
| Lower (<34.8) | 66 | 0.80 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.28-2.29 | .67 |
| Lower (<8.9) | 16 | 0.80 | ||
| CD4+ naive T cells (CD45RA+ CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.15-1.73 | .27 |
| Lower (<1.3) | 15 | 0.50 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.33-1.28 | .21 |
| Lower (<0.4) | 56 | 0.65 | ||
HR was adjusted for age, donor type, and DRI and used for disease-free and overall survival analysis. HR denotes an increased risk of mortality. Relative risk (RR) was adjusted for donor type and DRI and used for TRM and relapse analysis.